Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...

The company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value.

Fintel reports that on January 10, 2025, Jefferies downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to ...

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December ...

IGM Biosciences (IGMS – Research Report) received a Hold rating and a $2.00 price target from Jefferies analyst Roger Song today. The company’s ...

IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T ...

Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat ...

Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) - - Company reducing its workforce by 73% - - Cash and investments of $183.8 million (unaudited) as of December ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...